Intermittent Fasting for Prediabetes and Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how intermittent fasting affects metabolism in individuals with prediabetes or obesity. Researchers aim to determine if fasting benefits, such as better weight control and improved blood pressure, occur without actual weight loss. Participants will either fast one day a week or receive diet and activity advice. Ideal candidates have a BMI between 21 and 29, normal thyroid function, regular menstrual cycles if female, and a family history of type 2 diabetes or gestational diabetes. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on lifestyle interventions.
Will I have to stop taking my current medications?
Yes, participants must stop taking chronic medications, including oral contraceptive pills, to join this trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that intermittent fasting is generally safe. Studies have found that participants often experience health benefits, such as lower blood sugar, improved cholesterol levels, and weight loss.
Most people handle fasting well, though some may feel hungry, tired, or irritable. These feelings are usually mild and subside as the body adjusts. The reviewed studies reported no serious side effects. While fasting might require an adjustment period, it is considered safe for most people to try.12345Why are researchers excited about this trial?
Researchers are excited about intermittent fasting for prediabetes and obesity because it offers a unique approach compared to traditional treatments like medication and lifestyle changes focusing solely on diet and exercise. Intermittent fasting involves periodic calorie restriction, which may improve insulin sensitivity and aid in weight loss more effectively than constant dieting. The excitement also stems from its simplicity; fasting one day a week is easier to adopt and maintain for some people compared to more complex dietary regimens. Additionally, there's potential for it to provide metabolic benefits without the need for continuous calorie-counting or dietary restrictions.
What evidence suggests that intermittent fasting could be an effective treatment for prediabetes and obesity?
This trial will compare different approaches to intermittent fasting. Research has shown that intermittent fasting can aid in weight loss and improve the body's sugar processing. It can lower body weight, blood sugar levels, and HbA1c levels, which are crucial for preventing prediabetes from progressing to diabetes. Intermittent fasting might offer similar benefits to traditional calorie-counting diets, but without the need to track every meal. Early studies suggest that fasting may provide health benefits even without weight loss, potentially improving health independently of weight changes. Participants in this trial will either fast one day per week with or without weight maintenance or receive counseling on optimal diet and activity recommendations.23456
Who Is on the Research Team?
Pouneh Fazeli, MD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for men and women aged 25-45 with a BMI between 21-29, normal thyroid function, regular menstrual cycles for women, and a family history of type 2 diabetes. It's not suitable for those on chronic medications, pregnant or breastfeeding individuals, people with certain vitamin deficiencies or high cholesterol risks, those with eating disorders or substance abuse issues.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants will fast one day per week for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fasting
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator